{"prompt": "['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen Inc.', 'Appendix S:', 'Sample Serious Adverse Event Form', 'AMGEN', 'Clinical Trial Serious Adverse Event Report - Phase 1-4', 'New', 'CC-10004-P BOR-020', 'Nouly Amgen Within 24 Hours of knowledge of the evenz', 'Apremilast', 'Follow-up', 'Reminder: Enzer the SAE Information Invo RAVE and then send the paper Serious', 'Adverse Evenz Reporz', \"Please refer 10 your site's Serious Adverse Evenz Report Form for Amgen Safezy's County Fax Number\", \"and If Fax Is unavallable, Amgen Safety's Country emall address.\", '1. SITE INFORMATION', 'Site Number', 'Investigator', 'Country', 'Date of Report', 'Day', 'Month', 'Year', 'Reporter', 'Phone Number', 'Fex Number', '(', ')', '(', ')', '2. SUBJECT INFORMATION', 'Subject ID Number', 'Age et event breet', 'Sex', 'Race', 'If applicable, provide End of', 'Study date', 'F', 'M', '3.', 'SERIOUS ADVER SE EVENT - Information in this seczion must also be entered on the AE/Serious Adverse Evenz Summary CRF', 'Provide the date the Investigator became aware of this Serious Adverse Event Information: Day', 'Month', 'Year', 'Serious Adiverae Event Diagnonia or Syndrome', 'Chick', 'Relationship', 'Outcoma', 'Chackerly', 'If diagncais la unktown, enter Signa', 'Sertua', 'eart', 'la there e recconable possibility thet the event', 'of Event', '=', 'may have been caused by IPT', 'When Final Diagnonia la knowm, enter un', '=', '01 Rascived', 'aluca', 'If yes see section 10', 'Adverse Event', '02 Not', 'precedure', 'Data Sturied', 'Data Ended', 'belore', 'eg blapay', 'frat', '=', '03 Ratal', 'LES are , ever\u00e9 la enter the', 'dome: di', 'P', 'belad', 'Apremilact', '04', 'Cavas el Desth Chity a la not acceginbia,', 'as the a en', 'Dey Month Tae', 'Day Month Tear', 'Berlous 01 Fatal', '03 Required hospitalization', '06 Persistent or significant disabil ity incapacity', '07 Other medically', 'Criteria: 02 Immedialely life- threatening 04 Prolonged hospitalization', '08 Congenital anomaly. birth defect', 'important serious event', '4. HOSPITALIZATION', 'Date Admitted', 'Date Discharged', 'Dav', 'Month', 'Year', 'Dav', 'Month', 'Year', 'Was cubject hoopitalized or was a hoopitalization prolonged due to this', 'event?', 'No', 'Yes, r yes, please complete date(s):', '5. INVESTIGATIONAL PRODUCT (IP)', 'Initial Start Date', 'Prior to, or at time of Event', 'Action Taken with Product', 'Lot# and Berial #', 'Date of Dose', 'Dose', 'Route', 'Frequenay', 'un', 'Day', 'Month', 'Daty', 'Month', 'uz Perrarently', 'Year', 'Year', 'U3 Withheld', 'Apremilast', 'o', 'blinded', 'open label', 'o', 'FORM-015482 Cilical Trial SAE Report Phese 1-4 V10.0 Effective date: 23-April-2018', 'SAER Created: 02-April-2020', 'Page of 3', 'Confidential and Proprietary', '95', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen Inc.', 'Appendix S:', 'Sample Serious Adverse Event Form (Continued)', 'AMGEN', 'Clinical Trial Serious Adverse Event Report - Phase 1-4', 'New', 'CC-10004-PSOR-020', 'Notify Amgen Within 24 Hours of knowledge of the event', 'Apremilast (Otezia)', 'Follow-up', 'Reminder: Enter the SAE information into RAVE and then send the paper Serious', 'Adverse Event Report', 'Site Number', 'Subject ID Number', '6. CONCOMITANT MEDICATIONS (eg. chemotherapy', 'Any Concomitant Medications?', 'No Yes, If yes please complete:', 'Start Date', 'Medication Name(e)', 'Stop Date', 'Co-suspect', 'Continuing', 'Treatment Med', 'Dose', 'Route', 'Freq.', 'Dey', 'Venth', 'Year', 'Day', 'Month', 'Year', 'Nor', 'Yen', 'No/', 'Yesr', 'No-', '7. RELEVANT MEDICAL HISTORY (include dates, allergies and any relevant prior therapy)', '8. RELEVANT LABORATORY VALUES (include baseline values) Any Relevant Laboratory values?', 'No', 'Yes, If yes, please complete:', 'Test', 'Unit', 'Date', 'Dap', 'Verth', 'Year', '9. OTHER RELEVANT TESTS (diagnostics and procedures)', 'Any Other Relevant tests?', 'No', 'Yes, If yes, please complete:', 'Date', 'Additional Tests', 'Results', 'Units', 'De Verth', 'FORM-015482 Clinical Trial SAE Report - Phase 1-4 V 10.0 Effective date: 23-April-2018', 'SAER Created 02-April-2020', 'Page 2 of 3', 'Confidential and Proprietary', '96', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen Inc.', 'Appendix S:', 'Sample Serious Adverse Event Form (Continued)', 'AMGEN', 'Clinical Trial Serious Adverse Event Report - Phase 1-4', 'New', 'CC-10004-PSOR-020', 'Notify Amgen Within 24 Hours of knowledge of the event', 'Apremilast (Otezia)', 'Follow-up', 'Reminder: Enter the SAE information into RAVE and then send the paper Serious', 'Adverse Event Report', 'Site Number', 'Subject ID Number', '10. CASE DESCRIPTION (Provide narrative details of events listed in section 3) For each event in section 3, where relationship=Yes', 'please provide rationale.', 'Signature of Investigator or Designee', 'Title', 'Date', '/ confirm by signing this report that the information an this form, including', 'seriousness and cousality assessments, is being provided to Amgen by the', 'Investigator for this study, or by a Qualified Medical Peyson authorized by the', 'Investigator for this study.', 'FORM-015482 Clinical Trial SAE Report- - Phase 1-4 V 10.0 Effective date: 23-April-2018', 'SAER Created 02-April-2020', 'Page 3 of 3', 'Confidential and Proprietary', '97', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']", "completion": ""}